ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02879318 (A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
purposePre-existing and emerging molecular targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clinical practice. Tumor profiling through circulating tumor DNA (ctDNA) represents an important opportunity in PDAC because of the aggressive nature of the disease. Circulating tumor fraction (CTF) levels are highly variable within and between cancer types and influence the accuracy of plasma-based tumor profiling, and the variability and factors related to CTF levels in PDAC are not well understood. EXPERIMENTAL
designctDNA sequencing (PredicineATLAS) and clinical metadata from a cohort of 166 patients with metastatic PDAC (mPDAC) were generated as part of the PA.7 trial (NCT02879318). Patients were stratified into high CTF (>30% CTF; 35/166, 21.08%) and low CTF (131/166, 78.92%) groups for comparative analysis. Matched RNA sequencing data were available for 20 patients.
resultsHigh CTF was associated with lower overall survival (hazard ratio = 1.87; 95% confidence interval, 1.27-2.75; P = 0.0014) as well as clinical presentation that was indicative of higher disease burden, with CTF highest in patients that had liver metastases and distant metastases including bulky lymph nodes versus patients with no liver metastases (P < 0.001). Exploratory gene expression analysis revealed a positive association between CTF and upregulation of cell cycle-related pathways, which included those involving CDK4 (P = 0.0093) and MT2A (P = 0.012), as well as glycolytic (P = 0.0028) and basal-like (P = 0.029) subtyping genes.
conclusionsThese data demonstrate the heterogeneity of CTF and its associated factors in mPDAC, which converge toward an aggressive phenotype from both clinical and molecular standpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.